Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Dienogest

FDA-approved product (tablet, oral).

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Dienogest
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Menorrhagia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Pregnadien derivatives
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA56.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli33.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae37.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis30.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Dienogest in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.5 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.9 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.0 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-9.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Dienogest with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Clinical Trial With Combination of Dienogest/Ethytnilestradiol and Drosperidona/Ethyniestradiol

    NCT01557023 · start 2013-07-01

    Registered record
    Registry ID
    NCT01557023
    Conditions
    Metrorrhagia
    Interventions
    barrier methods; barrier methods
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    2013-07-01
    Completion
    2014-12-01
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetrorrhagia
    Interventionbarrier methods; barrier methods
    PhasePhase 3
    Registry statusWithdrawn

  • Gonadotropin-releasing Hormone (GnRH) Downregulation Versus Oral Anticonception Prior to ART in Postoperative Endometriosis Patients

    NCT02400801 · start 2013-06

    Registered record
    Registry ID
    NCT02400801
    Conditions
    Endometriosis; Infertility
    Interventions
    triptorelin; ethinylestradiol + dienogest
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2013-06
    Completion
    2018-01-26
    Enrolment
    166

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEndometriosis; Infertility
    Interventiontriptorelin; ethinylestradiol + dienogest
    PhaseNot applicable
    Registry statusCompleted

  • Comparative Study of BAY86-5300 With an Extended Flexible Regimen for Endometriosis

    NCT01697111 · start 2012-10

    Registered record
    Registry ID
    NCT01697111
    Conditions
    Endometriosis
    Interventions
    EE20/DRSP(BAY86-5300); Placebo; Dienogest
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-10
    Completion
    2014-12
    Enrolment
    312

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEndometriosis
    InterventionEE20/DRSP(BAY86-5300); Placebo; Dienogest
    PhasePhase 3
    Registry statusCompleted

  • Study of a 4-phasic Oral Contraceptive for the Treatment of Heavy Menstrual Bleeding

    NCT01638923 · start 2012-06

    Registered record
    Registry ID
    NCT01638923
    Conditions
    Metrorrhagia
    Interventions
    EV/DNG (Qlaira, Natazia, BAY86-5027); placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-06
    Completion
    2015-06
    Enrolment
    339

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetrorrhagia
    InterventionEV/DNG (Qlaira, Natazia, BAY86-5027); placebo
    PhasePhase 3
    Registry statusCompleted

  • Study of the Efficacy of Dienogest in the Treatment of Uterine Leiomyomas When Compared to Desogestrel and Goserelin

    NCT01738724 · start 2012-01

    Registered record
    Registry ID
    NCT01738724
    Conditions
    Uterine Leiomyoma
    Interventions
    Dienogest; Goserelin; Desogestrel
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2012-01
    Completion
    2017-12
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUterine Leiomyoma
    InterventionDienogest; Goserelin; Desogestrel
    PhasePhase 4
    Registry statusTerminated

  • Visanne Study to Assess Safety in Adolescents

    NCT01283724 · start 2011-03

    Registered record
    Registry ID
    NCT01283724
    Conditions
    Endometriosis
    Interventions
    Dienogest (Visanne, BAY86-5258)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2011-03
    Completion
    2014-06
    Enrolment
    111

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEndometriosis
    InterventionDienogest (Visanne, BAY86-5258)
    PhasePhase 2
    Registry statusCompleted

  • Cycle Control Assessment of a Combined Oral Contraceptive Containing Estetrol and a Progestin P1 or P2

    NCT01221831 · start 2010-09

    Registered record
    Registry ID
    NCT01221831
    Conditions
    Contraception
    Interventions
    estetrol, P 1 and placebo tablets; estetrol, P2 and placebo tablets; Estradiol valerate, dienogest and placebo tablets
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2010-09
    Completion
    2011-09
    Enrolment
    396

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionContraception
    Interventionestetrol, P 1 and placebo tablets; estetrol, P2 and placebo tablets; Estradiol valerate, dienogest and placebo tablets
    PhasePhase 2
    Registry statusCompleted

  • Bioequivalence Study: 2 mg Estradiol Valerate (EV) and 3 mg Dienogest (DNG) Without and With Levomefolate Calcium

    NCT00941057 · start 2009-09

    Registered record
    Registry ID
    NCT00941057
    Conditions
    Pharmacology, Clinical
    Interventions
    BAY 98-7079, Estradiolvalerate (EV) / Dienogest (DNG) / Levomefolate calcium; BAY 86-5027,Estradiolvalerate(EV) / Dienogest (DNG); BAY 86-7660,levomefolate calcium
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2009-09
    Completion
    2010-01
    Enrolment
    43

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPharmacology, Clinical
    InterventionBAY 98-7079, Estradiolvalerate (EV) / Dienogest (DNG) / Levomefolate calcium; BAY 86-5027,Estradiolvalerate(EV) / Dienogest (DNG); BAY 86-7660,levomefolate calcium
    PhasePhase 1
    Registry statusCompleted

  • Effects of SH T00658ID on Libido

    NCT00764881 · start 2009-01

    Registered record
    Registry ID
    NCT00764881
    Conditions
    Contraception; Libido
    Interventions
    EV/DNG (Qlaira, BAY86-5027, SH T00658ID); Microgynon; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2009-01
    Completion
    2010-07
    Enrolment
    217

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionContraception; Libido
    InterventionEV/DNG (Qlaira, BAY86-5027, SH T00658ID); Microgynon; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Effect of a New Oral Contraceptive Pill on Hormone Related Symptoms Such as Pelvic Pain and Headache

    NCT00778609 · start 2008-12

    Registered record
    Registry ID
    NCT00778609
    Conditions
    Oral Contraceptive; Headache; Pelvic Pain
    Interventions
    EV/DNG (Qlaira, BAY86-5027); Encapsulated Microgynon + Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2008-12
    Completion
    2010-12
    Enrolment
    449

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOral Contraceptive; Headache; Pelvic Pain
    InterventionEV/DNG (Qlaira, BAY86-5027); Encapsulated Microgynon + Placebo
    PhasePhase 3
    Registry statusCompleted

  • To Compare SH T00658ID Over Ortho Tri-Cyclen Lo (US/Canada)

    NCT00754065 · start 2008-09-08

    Registered record
    Registry ID
    NCT00754065
    Conditions
    Contraception
    Interventions
    Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027); Ortho Tri Cyclen Lo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2008-09-08
    Completion
    2011-05-10
    Enrolment
    409

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionContraception
    InterventionEstradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027); Ortho Tri Cyclen Lo
    PhasePhase 3
    Registry statusCompleted

  • Use of Oral Contraceptives (OCs) Containing Dienogest and Risk of Venous Thromboembolism

    NCT00523614 · start 2007-07

    Registered record
    Registry ID
    NCT00523614
    Conditions
    Venous Thromboembolism
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2007-07
    Completion
    2008-06
    Enrolment
    3,400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVenous Thromboembolism
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Valette (Combined Oral Contraceptive SH T04769G and SH D00659AF) Low Ovulation Inhibition

    NCT00471991 · start 2007-04

    Registered record
    Registry ID
    NCT00471991
    Conditions
    Oral Contraceptive
    Interventions
    SH T04769G; Ethinyl estradiol / dienogest (SH D00659 AF)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2007-04
    Completion
    2007-12
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOral Contraceptive
    InterventionSH T04769G; Ethinyl estradiol / dienogest (SH D00659 AF)
    PhasePhase 2
    Registry statusCompleted

  • Efficacy and Safety Study for the Treatment of Dysfunctional Uterine Bleeding

    NCT00307801 · start 2006-02

    Registered record
    Registry ID
    NCT00307801
    Conditions
    Metrorrhagia
    Interventions
    Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027); Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2006-02
    Completion
    2008-05
    Enrolment
    231

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetrorrhagia
    InterventionEstradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027); Placebo
    PhasePhase 3
    Registry statusCompleted

  • Efficacy and Safety Study for the Treatment of Dysfunctional Uterine Bleeding

    NCT00293059 · start 2005-12

    Registered record
    Registry ID
    NCT00293059
    Conditions
    Metrorrhagia
    Interventions
    Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027); Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2005-12
    Completion
    2008-05
    Enrolment
    190

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetrorrhagia
    InterventionEstradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027); Placebo
    PhasePhase 3
    Registry statusCompleted